← Back to patent-cliff list
GFH-276
Tier C — Watch / tradeGFH-276
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CYPA, Ras
Indications (approved)：Solid tumour, 胰腺导管癌, Pancreatic cancer, Non-small cell lung cancer, Colorectal cancer
Regional status
US
-
EU
-
China
Phase II
2025-09-22
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of GFH-276?
Approved indications include: Solid tumour, 胰腺导管癌, Pancreatic cancer, Non-small cell lung cancer, Colorectal cancer.
When does the GFH-276 patent expire?
No public expiry year is available for GFH-276 yet; this page updates once verified.
How do I get a quote for GFH-276 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30